Extracellular vesicles in venous thromboembolism and pulmonary hypertension

J Nanobiotechnology. 2023 Nov 30;21(1):461. doi: 10.1186/s12951-023-02216-3.

Abstract

Venous thromboembolism (VTE) is a multifactorial disease, and pulmonary hypertension (PH) is a serious condition characterized by pulmonary vascular remodeling leading with increased pulmonary vascular resistance, ultimately leading to right heart failure and death. Although VTE and PH have distinct primary etiologies, they share some pathophysiologic similarities such as dysfunctional vasculature and thrombosis. In both conditions there is solid evidence that EVs derived from a variety of cell types including platelets, monocytes, endothelial cells and smooth muscle cells contribute to vascular endothelial dysfunction, inflammation, thrombosis, cellular activation and communications. However, the roles and importance of EVs substantially differ between studies depending on experimental conditions and parent cell origins of EVs that modify the nature of their cargo. Numerous studies have confirmed that EVs contribute to the pathophysiology of VTE and PH and increased levels of various EVs in relation with the severity of VTE and PH, confirming its potential pathophysiological role and its utility as a biomarker of disease severity and as potential therapeutic targets.

Keywords: Diagnosis; Extracellular vesicles; Pathogenesis; Pulmonary hypertension; Treatment; Venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Endothelial Cells / metabolism
  • Extracellular Vesicles* / metabolism
  • Humans
  • Hypertension, Pulmonary* / metabolism
  • Hypertension, Pulmonary* / therapy
  • Thrombosis*
  • Venous Thromboembolism* / metabolism